Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates to enable biotech clients a seamless journey from early phase to later phase studies. Avance Clinical has backing from private equity group Riverside ...
Avance Clinical, the largest full-service Australian Contract Research Organization (CRO) for international biotechs, announced today the appointment of Liahna Toy to the new senior executive role, Head of Business Development.
Avance Clinical, the largest premium Australian Contract Research Organization (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region.
Avance Clinical's client XWPharma Ltd. has announced dosing of subjects in its first-in-human study evaluating XW10508, the Company’s novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain.
Avance Clinical has been awarded the prestigious Frost & Sullivan 2021 Asia-Pacific CRO Customer Value Leadership Award, the second consecutive Asia-Pacific (APAC) CRO Best Practices Award for the company from Frost & Sullivan.
The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing.
Avance Clinical is a full-service Contract Research Organization (CRO) with clinical operations in Australia, New Zealand, Asia, North America, and Europe.
Level 22, 91 King William Street
Adelaide, SA
Australia 5000
Phone: +61 8 8249 4788
For all media enquiries: media@avancecro.com